Brand Name

Intuniv

Generic Name
Guanfacine
View Brand Information
FDA approval date: October 17, 1995
Classification: Central alpha-2 Adrenergic Agonist
Form: Tablet

What is Intuniv (Guanfacine)?

INTUNIV ® is indicated for the treatment of Attention Deficit Hyperactivity Disorder as monotherapy and as adjunctive therapy to stimulant medications. INTUNIV ® is a central alpha 2A -adrenergic receptor agonist indicated for the treatment of Attention Deficit Hyperactivity Disorder as monotherapy and as adjunctive therapy to stimulant medications .
Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs

Summary: The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treati...

Randomized Controlled Trial (RCT) of Open Debridement Versus Percutaneous Ultrasonic Treatment for Symptomatic Lateral Epicondylitis.

Summary: Lateral epicondylitis (Tennis Elbow) can cause pain and keep individuals from completing their daily activities and require them to miss work. There are currently different treatment options to address tennis elbow. However surgeons do not know if one is better than the other. This study will compare two treatment options for tennis elbow. Participants will either be treated by Ultrasound-guided P...

Guanfacine for Alcohol Use Disorder (AUD): a Telehealth Approach

Summary: The investigators assess whether guanfacine extended release (GXR; 3mg/d) compared with placebo (PBO) will attenuate drinking and drinking-related factors in N=200 men and women with Alcohol Use Disorder (AUD) across 12-weeks.

Related Latest Advances